Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studies

Irish Veterinary Journal

David McGahie²  Elodie Benizeau¹  Nolwenn Crastes¹  Christelle Navarro² 

[1] R&D, Virbac, 13ème rue LID, Carros, 06515, France;Medical department, Virbac, 13ème rue LID, Carros, 06515, France

关键词: Compliance;    Consumption;    Voluntary acceptance;    Prehension;    Intake;    Ciclosporin;    Dog;    Atopic dermatitis;   

Others  :  1133502
DOI  :  10.1186/s13620-015-0031-8

 received in 2014-11-21, accepted in 2015-01-23,  发布年份 2015

【 摘 要 】

Background

Atopic dermatitis (AD) is the most common canine allergic skin disease and can significantly affect the quality of life of affected dogs. Treating canine AD with ciclosporin has been a subject of great interest in recent years. Many studies have provided substantial evidence of ciclosporin efficacy and safety in canine AD management, and for several years ciclosporin has been recognised as a major component of canine AD multimodal therapy. As a chronic condition, canine AD requires life-long medical management and treatment success relies in large part on product ease of administration. Two studies were conducted to assess the comparative voluntary acceptance and consumption of Cyclavance® (Virbac), a new oral liquid formulation of ciclosporin, and Atopica® (Novartis) either added to a small quantity of kibbles (study 1) or administered directly into the dog’s mouth (study 2).

Results

Over the course of the two studies 70 dogs assessed each of the ciclosporin formulations and 320 individual tests were performed for each tested product. Immediate prehension (in less than 2 seconds) occurred significantly more often with Cyclavance® (90.6% of the tests) than with Atopica® (14.4% of the tests) when products were mixed with 30 grams of dry food (p < 0.001). Moreover, Cyclavance® was significantly more often easily accepted than Atopica® (99.3% vs 27.1% of the tests, respectively) when products were administered directly into the dogs’ mouth (p < 0.0001). Cyclavance® was also more often totally consumed (98.3% of the tests) than Atopica® (2.2% of the tests) when mixed with a small amount of food (p < 0.001). However, both products were totally consumed once administered directly into the dogs’ mouth.

Conclusions

By facilitating cicloporin administration and consumption, Cyclavance® liquid formulation offers an interesting alternative to capsules that may improve dosing compliance and therefore the ability to benefit from the therapeutic effects in the long-term treatment of canine AD.

【 授权许可】

   
2015 Navarro et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 2.

【 参考文献 】

• [1]DeBoer DJ: Ciclosporin in canine dermatology: a decade of comfort. Vet Rec 2014, 174:1-2.
• [2]Guaguère E, Steffan J, Olivry T: Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol 2004, 15:61-74.
• [3]Forsythe P, Paterson S: Ciclosporin 10 years on: indications and efficacy. Vet Rec 2014, 174(suppl 2):13-21.
• [4]Radowicz S, Power H: Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Vet Dermatol 2005, 16:81-86.
• [5]Moxham G: Waltham feces scoring system – a tool for veterinarians and pet owners: how does your pet rate? Waltham® Focus 2001, 11:24-25.
• [6]Gordon S, Kittleson M: Drugs used in the management of heart disease and cardiac arrhythmias. In Small animal clinical pharmacology. 2nd edition. Edited by Maddison J, Page SW, Church DB. Elsevier, Philadelphia; 2008:412-418.
• [7]Thombre AG. Canine acceptability of flavoured placebo tablets. In 29th Proceedings of Internal Symposium on Control. Release Bioact Mater. 2002:116
• [8]Waterhouse HN, Fritsch CW: Dog food palatability tests and sources of potential bias. Lab Anim Care 1967, 17:93-102.
• [9]Thombre AG: Oral delivery of medications to companion animals: palatability considerations. Adv Drug Delivery Rev 2004, 56:1399-1413.
• [10]Steffan J, Strehlau G, Maurer M, Rohlfs A: Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Therap 2004, 27:231-238.
• [11]Palmeiro BS: Cyclosporine in Veterinary Dermatology. Vet Clin Small Anim 2013, 43:153-171.
• [12]Thelen A, Mueller RS, Linek M, Peters S, Stechmann K, Steffan J: Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis. Vet Rec 2006, 159:854-856.
• [13]Steffan J, Favrot C, Mueller R: A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006, 17:3-16.
• [14]Steffan J, Parks C, Seewald W: Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc 2005, 226:1865-1863.
• [15]Nuttall T, Reece D, Roberts E: Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec 2014, 174(suppl 2):3-12.
• [16]Dip R, Carmichael J, Letellier I, Strehlau G, Roberts E, Bensignor E, Rosenkrantz W: Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis. Vet Res 2013, 9:173.